HCPLive interview
At the 2026 American Thoracic Society International Conference, investigator Robert Wallis, MD, the chief science officer at the Aurum Institute & professor of medicine at Vanderbilt University, presented preliminary findings from the PanTB-HM phase 2c trial, which evaluated 3 novel 4-month pan-TB regimens, each containing the investigational oxazolidinone sutezolid, against standard 6-month HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) therapy in 378 adults across South Africa, Tanzania, and Mozambique.
Among participants with impaired baseline lung function (FEV1 ≤62%), recipients of the S1600BPN regimen — sutezolid 1600 mg, bedaquiline, pretomanid, and N-acetylcysteine (NAC) — demonstrated markedly superior FEV1 recovery compared with controls, a 10.6 percentage point difference at day 14 that was largely maintained through day 168. No typical oxazolidinone adverse events were observed across any experimental arm.
HCPLive spoke with Wallis during the meeting to discuss what these results may mean for clinicians managing TB-associated lung disease and the evolving role of sutezolid and NAC in next-generation TB regimens.
Read the full interview here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #17, 11 June 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : HCPLive
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.